Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
Merck (NYSE:MRK) received FDA approval for expanded use of Keytruda and Keytruda QLEX combinations with Padcev in muscle-invasive bladder cancer. The decision is based on results from the pivotal Phase 3 KEYNOTE-B15 study. This is the first PD-1 inhibitor plus antibody drug conjugate regimen cleared for these patients regardless of cisplatin eligibility. The latest approval adds another indication for Merck's flagship oncology drug Keytruda. It reinforces the company’s presence in bladder...
The results were seen by Wall Street analysts as “direct proof-of-concept” that sac-TMT, a drug Merck views as a “cornerstone,” could be part of a future treatment standard for front-line lung cancer.
Johnson and Johnson just raised its full-year outlook toward a historic $100 billion revenue target, yet the stock still trades well below where our model says it should be. The real question is whether the pipeline can outrun the headwinds closing in fast.
PFE's oncology business is in focus ahead of Q2 results as growth from key cancer drugs, biosimilars and pipeline updates may offset declines in older therapies.
BMY's FDA filing for mezigdomide in relapsed or refractory multiple myeloma marks another step in advancing its protein degrader pipeline.
Merck & Co. is expected to announce its second-quarter earnings in August, and Wall Street forecasts a double-digit decline in its profits.
Eli Lilly has whipsawed shareholders in 2026, but one under-the-radar catalyst in its pipeline could change the trajectory entirely. Here is what the bulls are watching that most investors are still sleeping on.
For investors seeking exposure to biotechnology's future, Incyte presents a clearer forward picture of accelerating growth, while the larger Regeneron asks for more faith in its pipeline.
Merck's Keytruda in combination with Pfizer's Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, regardless of cisplatin eligibility.
At $1,189, Eli Lilly (LLY) looks set up for roughly 76% of upside over the next three years under a conservative scenario. That is a move large enough to justify digging into where it comes from. Revenue compounding does the work, but the multiple takes a meaningful cut along the way. Here is the operational reality the math is built on.
Merck stock has delivered an 87.4% return over the past 5 years. The current Discounted Cash Flow (DCF) estimate now points to meaningful upside relative to the US$123.54 share price, while the broader valuation checks paint a more mixed picture. Over 5 years, Merck has returned 87.4%. This puts current buyers in the position of judging whether that past compounding already reflects much of the company’s progress. Ongoing expansion of the Keytruda and broader oncology pipeline may support...
SLS leads in stock momentum, while MLTX is cheaper and better-funded, with nearly $300 million in cash at the end of the first quarter.
U.S. Central Command said that American forces had begun launching further strikes against Iran to thwart their ability “to attack civilian mariners and commercial ships freely transiting the Strait of Hormuz.”
In the closing of the recent trading day, Merck (MRK) stood at $123.54, denoting a -1.22% move from the preceding trading day.
Merck & Co. has outperformed the S&P 500 in 2026, rising 19% year-to-date while offering a 2.61% dividend yield supported by 15 consecutive years of dividend increases.
Exelixis' zanzalintinib faces a setback, but an FDA review, phase III trials and Cabometyx momentum keep investors focused on its growth path.
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Merck (MRK) has reached a new access agreement with the ADAP Crisis Task Force for its once daily HIV treatment IDVYNSO. This development gives investors fresh context for assessing the stock. See our latest analysis for Merck. Merck shares recently pulled back, with a 1-day share price return declining 2.23% to close at US$125.99. However, the 30-day share price return of 5.41% and 1-year total shareholder return of 55.54% point to momentum that remains broadly positive. If Merck’s recent...
In late June 2026, Merck reported multiple oncology milestones, including U.S. FDA approval of KEYTRUDA and KEYTRUDA QLEX plus Trodelvy for first-line PD-L1–positive advanced triple-negative breast cancer and EU approval of KEYTRUDA plus Padcev for cisplatin-ineligible muscle-invasive bladder cancer. These approvals further entrench KEYTRUDA at the center of Merck’s cancer portfolio, broadening its use across hard-to-treat tumors while the company prepares for future loss of...
Tesla, Bank of America and Merck lead today's featured research, highlighting growth drivers, risks and outlooks shaping these widely watched stocks.
By Karen Roman Redwire Corporation (NYSE: RDW) said it designated Paul Reichert and Niki Werkheiser to serve at strategic advisory roles at Space Microgravity Development (SpaceMD), Redwire’s venture company focused […]